Impact & Research
Our Work
Equitable access to biomarker testing and personalized cancer care must be a standard of care for all Canadian patients, regardless of age, location, or income.
Policy Paper (July 2022)
The BEAT Cancer Coalition recommends that governments enable equitable access to the appropriate advanced molecular diagnostic testing through comprehensive genomic profiling (CGP), for all cancer patients across Canada.
The treatment landscape for cancer has evolved significantly over the past few decades, with a shift towards personalized healthcare for individual patients. Cancer therapies are now being developed based on key molecular drivers within the genomic profile of individual tumours.
Despite these advancements, patients today still suffer from the one-size-fits-all approach to treatment, lacking access to advanced diagnostics and being subjected to sequential rounds of therapy that may or may not be successful.
” 63% of patients unaware of biomarker-guided treatment at diagnosis.”
"All Canadian oncology patients, regardless of where they live, should receive timely and appropriate advanced molecular testing in order to receive the optimal therapy for them, giving them the greatest chance of treatment success and the greatest opportunity to live their best life."
Biomarker Testing Video Series
Hear directly from Canadian experts as they explain what biomarker testing is, how it works, and the value it brings to patients living with cancer.
“Biomarker testing reveals the unique molecular profile of a tumour — it’s how we ensure the right treatment for the right patient at the right time.” — Dr. Brandon Sheffield
English
French
French
French
Funding Acknowledgements
